Cross Country Healthcare Reports Q4 2025 Revenue Decline of 24%, Full Year Down 22% Amid Ongoing Staffing Downturn

What happened

Cross Country Healthcare announced its fourth quarter and full-year 2025 financial results, showing continued revenue contraction in its core travel nurse and allied segments. Q4 2025 revenue fell 24% year-over-year to $236.8 million and 5% sequentially, while full-year revenue dropped 22% to $1.054 billion, underscoring the persistent normalization from pandemic peaks. This aligns with the DeepValue report's findings of a severe downcycle, where nurse and allied contribution income has plummeted and diversification into homecare and physician staffing has not offset the declines. Management's efforts, including MSP contract renewals and a $40 million buyback authorization, are overshadowed by the revenue erosion, which threatens EBITDA margin recovery targets. The lack of stabilization in key metrics suggests the company is still grappling with cyclical headwinds, challenging the investment thesis that hinges on a near-term bottom.

Implication

The persistent revenue decline indicates the travel nurse normalization is more prolonged than hoped, directly undermining the base case scenario of stabilization within 6-12 months. With full-year revenue down 22%, achieving the targeted 3-4% EBITDA margin becomes increasingly difficult, raising risks of continued losses and cash flow pressure. While the net cash position and buyback authorization provide a cushion, ongoing declines could erode this safety net, limiting capital allocation options and increasing reliance on cost cuts. Investors should closely monitor upcoming quarters for signs of volume stabilization in nurse and allied FTEs, as per DeepValue checkpoints, to gauge if the bear scenario with further downside is materializing. In the near term, the absence of positive catalysts and sustained top-line weakness may keep the stock under pressure, necessitating a patient approach and potential reassessment of entry points below current levels.

Thesis delta

The new results confirm that revenue stabilization is not yet occurring, shifting the thesis towards a more cautious stance where the bear scenario of persistent double-digit declines gains probability. This weakens the base case assumption of moderation in 2026, emphasizing that investors must wait for clearer evidence of bottoming in core segments before expecting margin recovery. The balance-sheet strength remains a key buffer, but the thesis now relies more heavily on management's ability to execute cost controls and buybacks amid ongoing top-line pressure.